奥泰生物(688606) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 208,475,751.58, representing a year-on-year increase of 4.28% compared to CNY 199,920,896.28 in the same period last year[4] - Net profit attributable to shareholders was CNY 61,216,292.50, a significant increase of 36.68% from CNY 44,788,913.62 in the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 58,348,017.52, reflecting a 54.45% increase from CNY 37,777,315.36 year-on-year[4] - The basic earnings per share increased to CNY 0.77, up 37.50% from CNY 0.56 in the same period last year[4] - The weighted average return on net assets rose to 1.59%, an increase of 0.42 percentage points from 1.17% in the previous year[4] - Total revenue for Q1 2025 reached ¥208,475,751.58, an increase of 4.3% compared to ¥199,920,896.28 in Q1 2024[19] - Net profit for Q1 2025 was ¥61,179,020.99, up 37.0% from ¥44,644,329.67 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.77, compared to ¥0.56 in Q1 2024, representing a 37.5% increase[21] - The company reported a significant increase in investment income, rising to ¥517,478.78 from ¥4,204,435.81 in the previous year[20] - The company’s total comprehensive income for Q1 2025 was CNY 66,119,495.05, compared to CNY 51,953,066.44 in Q1 2024[30] Cash Flow and Assets - The net cash flow from operating activities decreased by 72.51%, amounting to CNY 10,745,190.17 compared to CNY 39,081,462.52 in the same period last year[4] - Operating cash inflow for Q1 2025 was CNY 218,921,277.15, an increase from CNY 203,888,757.66 in Q1 2024, representing a growth of approximately 7.5%[23] - Net cash flow from operating activities for Q1 2025 was CNY 10,745,190.17, a significant decrease from CNY 39,081,462.52 in Q1 2024, indicating a decline of about 72.5%[24] - Cash inflow from investment activities in Q1 2025 was CNY 599,607,891.80, down from CNY 866,426,537.50 in Q1 2024, reflecting a decrease of approximately 30.9%[24] - Cash and cash equivalents amounted to CNY 896.27 million, down from CNY 920.38 million, reflecting a decrease of 2.41%[13] - Cash and cash equivalents at the end of Q1 2025 were CNY 876,232,053.16, down from CNY 1,239,986,125.64 at the end of Q1 2024, a decline of approximately 29.3%[24] - The company experienced a net decrease in cash and cash equivalents of -CNY 24,104,902.43 in Q1 2025, compared to -CNY 76,639,100.24 in Q1 2024, showing an improvement in cash flow management[24] - Total assets at the end of the reporting period were CNY 4,204,870,426.23, a slight increase of 0.45% from CNY 4,186,020,158.25 at the end of the previous year[5] - Total assets amounted to ¥4,204,870,426.23, slightly up from ¥4,186,020,158.25[16] - Current assets totaled CNY 3,399,417,450.72 as of March 31, 2025, compared to CNY 3,282,646,855.51 at the end of 2024, marking an increase of approximately 3.5%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,431[8] - The company has a total of 52.76% of shares controlled by its actual controllers, indicating a strong ownership structure[11] - The top ten shareholders hold a significant portion of the company's shares, with the largest shareholder owning 18.49 million shares, representing a substantial stake[11] - The company has a repurchase account holding 1.41 million shares, accounting for 1.78% of total shares, which is not included in the top ten shareholders[12] - The company has signed a "consensus action agreement" among its major shareholders, ensuring aligned interests in management and strategic decisions[11] Expenses and Liabilities - Research and development expenses totaled CNY 21,152,185.22, accounting for 10.15% of revenue, down from 11.58% in the previous year[5] - Total operating costs decreased to ¥143,277,319.88 from ¥144,138,319.97, reflecting a slight reduction of 0.6%[19] - Research and development expenses for Q1 2025 were ¥21,152,185.22, a decrease of 8.7% from ¥23,156,697.04 in Q1 2024[20] - Total liabilities decreased to ¥257,185,156.86 from ¥302,599,855.36, indicating a reduction of 15.0%[16] - Total liabilities decreased to CNY 161,338,001.91 as of March 31, 2025, from CNY 171,803,877.54 at the end of 2024, indicating a reduction of about 6.1%[28] - The company experienced a decrease in sales expenses, which rose to ¥14,008,023.23 from ¥10,813,141.14, indicating a 29.8% increase[19] - The company experienced a significant decrease in financial expenses, reporting CNY -587,080.88 in Q1 2025 compared to CNY -4,403,744.85 in Q1 2024[29]